ReviewInternational journal of clinical oncology2022
A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study.
Review in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- Propensity score-matched comparison of survival outcomes between clear cell and non-clear cell renal cell carcinoma in cT1N0M0 disease.International journal of clinical oncology · 2026Article
- Local treatment for metastatic and primary sites in metastatic renal cell carcinoma in the combination immunotherapy era: a narrative review.International journal of clinical oncology · 2026Review
- Intussusception caused by metastatic renal cell carcinoma at the duodenojejunal junction 41 years after nephrectomy: a case report.International journal of surgery case reports · 2026Article
- Application of contrast-enhanced CT-based radiomics with machine learning to predict WHO/ISUP grading in clear cell renal cell carcinoma.BMC cancer · 2026Article
- Initial report of prospective study of regional cooperation for imaging-based follow-up after curative renal cell carcinoma surgery.Scientific reports · 2025Observational
- Editorial Comment on Advances in Adjuvant Therapy for Renal Cell Carcinoma: Perspectives on Risk Stratification and Treatment Outcomes.International journal of urology : official journal of the Japanese Urological Association · 2025Article
- Computed tomography-based radiomics predicts prognostic and treatment-related levels of immune infiltration in the immune microenvironment of clear cell renal cell carcinoma.BMC medical imaging · 2025Article
- Incidence and Pattern of Recurrence after Surgical Resection in Organ-Confined Renal Cell Carcinoma.Yonsei medical journal · 2024Article
- Machine learning analysis for detecting late recurrence and loss to follow-up after renal cell carcinoma surgery.BJUI compass · 2024Article
- Does tumor rupture during robot-assisted partial nephrectomy have an impact on mid-term tumor recurrences?Radiology and oncology · 2023Article
- OCLN as a novel biomarker for prognosis and immune infiltrates in kidney renal clear cell carcinoma: an integrative computational and experimental characterization.Frontiers in immunology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLate recurrence of renal cell carcinoma (RCC) is observed in some postoperative patients. In addition, some of these patients are lost to long-term postoperative follow-up. We reviewed the treatment results and prognosis of postoperative patients with RCC at Chiba University Hospital, with the aim of clarifying the proportion and background of patients lost to follow-up.
methodsThis retrospective study included 1176 RCC patients who underwent radical or/and partial nephrectomy. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and lost follow-up free survival (LFFS) were evaluated and the risk factors for LFFS identified.
resultsThe median RFS for stage II and II cases was 188.3 and 104.0 months, respectively. Even in stage I, recurrence was observed in about 20% of patients 20 years after surgery. The Kaplan-Meier curve for LFFS showed a linear descent over time, with 50% of patients lost to follow-up within 25 years. Older age (≥ 62 years), histological type (clear cell RCC), and no recurrence were significant risk factors for lost follow-up.
conclusionsLong-term follow-up is necessary after RCC surgery because late recurrence cases are not uncommon. We believe that lifelong follow-up with imaging studies is recommended for postoperative RCC patients. Early detection of recurrence in postoperative patients is a very important issue, and it may be worthwhile for improving the prognosis of postoperative patients to focus on patients lost to follow-up who may have been overlooked.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.